These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
851 related articles for article (PubMed ID: 28280301)
1. Eteplirsen in the treatment of Duchenne muscular dystrophy. Lim KR; Maruyama R; Yokota T Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301 [TBL] [Abstract][Full Text] [Related]
2. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
3. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update. Sheikh O; Yokota T Arch Toxicol; 2022 Jan; 96(1):1-9. PubMed ID: 34797383 [TBL] [Abstract][Full Text] [Related]
4. Eteplirsen: First Global Approval. Syed YY Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823 [TBL] [Abstract][Full Text] [Related]
13. Viltolarsen for the treatment of Duchenne muscular dystrophy. Roshmi RR; Yokota T Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560 [TBL] [Abstract][Full Text] [Related]
14. Eteplirsen for the treatment of Duchenne muscular dystrophy. Mendell JR; Rodino-Klapac LR; Sahenk Z; Roush K; Bird L; Lowes LP; Alfano L; Gomez AM; Lewis S; Kota J; Malik V; Shontz K; Walker CM; Flanigan KM; Corridore M; Kean JR; Allen HD; Shilling C; Melia KR; Sazani P; Saoud JB; Kaye EM; Ann Neurol; 2013 Nov; 74(5):637-47. PubMed ID: 23907995 [TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping. Mercuri E; Seferian AM; Servais L; Deconinck N; Stevenson H; Ni X; Zhang W; East L; Yonren S; Muntoni F; Neuromuscul Disord; 2023 Jun; 33(6):476-483. PubMed ID: 37207382 [TBL] [Abstract][Full Text] [Related]
16. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis. Randeree L; Eslick GD J Clin Neurosci; 2018 Mar; 49():1-6. PubMed ID: 29254734 [TBL] [Abstract][Full Text] [Related]
17. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative Viewpoint. Irwin AN; Herink MC Pharmacotherapy; 2017 Oct; 37(10):e109-e111. PubMed ID: 28741800 [No Abstract] [Full Text] [Related]
18. Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy. Nguyen Q; Yokota T J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29035327 [TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Guncay A; Yokota T Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833 [No Abstract] [Full Text] [Related]
20. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases. Rodrigues M; Yokota T Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]